Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients.

Next Previous
Trial Profile

An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 18 Sep 2014 The Primary endpoint assessment (OS) duration changes from "assumption of 2 yrs" to "until death due to any cause or study close, whichever occurred first (assessed up to a maximum of 1290 Days)" according to ClinicalTrials.gov
  • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 01 Feb 2013 Planned End Date changed from 1 Mar 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top